Pharsight

Seglentis generic

Seglentis is a pain medication owned by Kowa Pharms, containing active ingredients Celecoxib and Tramadol Hydrochloride. It was first authorized for market use on October 15, 2021.

When will Seglentis generic be available?

The release of generic versions of Seglentis is possible after June 3, 2031. This is based on the expiry date of its last patent - US8846744, which holds until that date.

Seglentis uses

Seglentis is primarily used for the treatment of pain in adults. Its effectiveness relies upon the synergistic actions of its two active ingredients - Tramadol Hydrochloride and Celecoxib.

Seglentis patent expiration

Seglentis has a total of 7 patents. The last patent that affects the release of Seglentis generic is US8846744, and it expires on June 3, 2031. Below are the details of the patent:

Seglentis dosage

Want to ask something?